H. Ascher-Svanum

J. Mccombs, H. Ascher-Svanum, Lizheng Shi, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

R. Baker, H. Ascher-Svanum, A. Shekhar, 2007, Schizophrenia bulletin.

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone

M. Olfson, S. Marcus, H. Ascher-Svanum, 2006, Schizophrenia bulletin.

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

R. Conley, H. Ascher-Svanum, B. Kinon, 2007, Schizophrenia Research.

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.

H. Ascher-Svanum, B. Kinon, S. Tunis, 2006, Journal of clinical psychopharmacology.

The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry.

H. Ascher-Svanum, D. Faries, F. Ernst, 2007, Primary care companion to the Journal of clinical psychiatry.

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients

H. Ascher-Svanum, D. Faries, P. Haddad, 2009, BMC psychiatry.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

P. Weiden, H. Ascher-Svanum, B. Kinon, 2014, Clinical schizophrenia & related psychoses.

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

J. Haro, H. Ascher-Svanum, Michihiro Takahashi, 2012, Pragmatic and observational research.

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis

R. Heine, Dara L. Schuster, D. Kendall, 2015, Diabetes Therapy.

Item response analysis of the Positive and Negative Syndrome Scale

R. Obenchain, H. Ascher-Svanum, J. Lindenmayer, 2007, BMC Psychiatry.

Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial

J. Rabinowitz, S. Levine, H. Ascher-Svanum, 2012, Schizophrenia Research.

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

R. Newton, H. Ascher-Svanum, L. Chuo, 2010, Patient preference and adherence.

A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms

I. Lipkovich, H. Ascher-Svanum, B. Kinon, 2006, Journal of clinical psychopharmacology.

Characteristics of Outpatients Initiated on Olanzapine versus Risperidone in the Treatment of Schizophrenia in Japan: A Healthcare Database Analysis

H. Ascher-Svanum, Michihiro Takahashi, W. Ye, 2011 .

Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia

P. Weiden, P. Llorca, H. Ascher-Svanum, 2014, Journal of clinical psychopharmacology.

Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools

Haya Ascher-Svanum, Leslie Citrome, Mauricio Tohen, 2007, Current medical research and opinion.

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

J. Lieberman, R. Conley, M. Case, 2011, Psychiatry Research.

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

J. Kane, H. Ascher-Svanum, B. Kinon, 2008, Schizophrenia Research.

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

S. Kapur, J. Kane, H. Ascher-Svanum, 2010, Neuropsychopharmacology.

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy

T. Treuer, H. Ascher-Svanum, M. Stensland, 2013, ClinicoEconomics and outcomes research : CEOR.

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

S. Kapur, D. Naber, H. Ascher-Svanum, 2010, Schizophrenia Research.

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs

H. Fu, H. Ascher-Svanum, A. Ali, 2016, Journal of managed care & specialty pharmacy.

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

J. Haro, H. Ascher-Svanum, H. Detke, 2013, BMC Psychiatry.

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

R. Conley, H. Ascher-Svanum, Michihiro Takahashi, 2012, Neuropsychiatric disease and treatment.

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

J. Kane, H. Ascher-Svanum, B. Kinon, 2011, ClinicoEconomics and outcomes research : CEOR.

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

S. Kapur, M. Case, H. Ascher-Svanum, 2011, Schizophrenia Research.

Costs associated with attempted suicide among individuals with bipolar disorder.

H. Ascher-Svanum, D. Ball, Baojin Zhu, 2010, The journal of mental health policy and economics.

Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database

A. Siderowf, T. Beach, J. Gaugler, 2013, BMC Geriatrics.

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

R. Conley, R. Klein, H. Ascher-Svanum, 2011, Current medical research and opinion.

Cost Effectiveness and Resource Allocation Cost-effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States

R. Conley, R. Klein, H. Ascher-Svanum, 2022 .

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2007, Patient preference and adherence.

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

H. Ascher-Svanum, P. Feldman, W. Montgomery, 2012, International journal of general medicine.

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

H. Ascher-Svanum, D. Faries, F. Ernst, 2004, Annals of general hospital psychiatry.

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.

H. Ascher-Svanum, J. Mauskopf, C. Graham, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Christian R. Dolder, H. Ascher-Svanum, J. Lacro, 2008, Patient preference and adherence.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

M. Witte, H. Ascher-Svanum, D. Faries, 2011, European Psychiatry.

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

K. Schuh, H. Ascher-Svanum, B. Kinon, 2013, Neuropsychiatric disease and treatment.

Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis: A 2-Year Prospective Study

M. Case, J. Rabinowitz, S. Levine, 2010, Journal of clinical psychopharmacology.

The heterogeneity of antipsychotic response in the treatment of schizophrenia

S. Kapur, R. Conley, J. Kane, 2010, Schizophrenia Research.

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12‐month observational study

H. Ascher-Svanum, Z. Kadziola, A. Brnabic, 2011, International journal of clinical practice.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia

K. Schuh, M. Case, M. Witte, 2012, Current medical research and opinion.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

K. Schuh, M. Case, H. Ascher-Svanum, 2011, Patient preference and adherence.

Early Onset of Antipsychotic Action in Schizophrenia: Evaluating the Possibility of Shorter Acute Efficacy Trials

S. Kapur, H. Ascher-Svanum, B. Kinon, 2010, Journal of clinical psychopharmacology.

PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY

J. Kane, H. Ascher-Svanum, B. Kinon, 2010 .

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2009, BMC psychiatry.

Cost Effectiveness and Resource Allocation Open Access Methodological Issues in Assessing Changes in Costs Pre-and Post-medication Switch: a Schizophrenia Study Example

H. Ascher-Svanum, D. Faries, A. Nyhuis, 2022 .

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2008, Current medical research and opinion.

Predicting a ‘Combined Treatment Outcome’ in Chronic Schizophrenia: The Role of Demographics, Symptomatology, Functioning and Subjective Well-being

S. Kapur, J. Chen, J. Kane, 2013, Pharmacopsychiatry.

S.05.02 Early response as a response predictor: use of individual variability in clinical trials

J. Kane, H. Ascher-Svanum, B. Kinon, 2009, European Neuropsychopharmacology.

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

H. Ascher-Svanum, T. Ohmori, Michihiro Takahashi, 2012, Pragmatic and observational research.

Clinical and functional outcomes for patients with schizophrenia treated with olanzapine: One-year naturalistic outcomes for inpatients and outpatients in Japan

H. Ascher-Svanum, Michihiro Takahashi, W. Ye, 2011 .

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder*

P. Kulkarni, H. Ascher-Svanum, Baojin Zhu, 2007, Current medical research and opinion.

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1‐year naturalistic study of schizophrenia patients in Japan

H. Ascher-Svanum, T. Ohmori, Michihiro Takahashi, 2012, Psychiatry and clinical neurosciences.

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

H. Ascher-Svanum, D. Faries, A. Nyhuis, 2009 .

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

R. Conley, R. Klein, H. Ascher-Svanum, 2022 .

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial

H. Ascher-Svanum, B. Kinon, T. Sugihara, 2012, BMC Medical Research Methodology.

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

J. Haro, H. Ascher-Svanum, H. Detke, 2014, Neuropsychiatric disease and treatment.

PMH5 Does Participation in a Weight Control Program Also Improve Clinical and Functional Outcomes for Chinese Patients with Schizophrenia Treated with Olanzapine

T. Treuer, H. Ascher-Svanum, Z. Kadziola, 2012 .

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study

J. Rabinowitz, S. Levine, H. Ascher-Svanum, 2011, Schizophrenia Research.

Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia

S. Marder, H. Ascher-Svanum, Lizheng Shi, 2007 .

Item response analysis of the Positive and Negative Syndrome Scale

R. Obenchain, H. Ascher-Svanum, J. Lindenmayer, 2007, BMC Psychiatry.

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

T. Treuer, H. Ascher-Svanum, Z. Kadziola, 2014, Neuropsychiatric disease and treatment.

Costs of treating patients with schizophrenia who have illness-related crisis events

H. Ascher-Svanum, D. Salkever, D. Faries, 2008, BMC psychiatry.

PMH2 EARLY RESPONSE PREDICTS SUBSEQUENT RESPONSE TO OLANZAPINE LONG-ACTING INJECTIONS IN THE TREATMENT OF SCHIZOPHRENIA

M. Witte, H. Ascher-Svanum, A. Nyhuis, 2010 .

Clinicoeconomics and Outcomes Research Dovepress Cost-effectiveness of Early Responders versus Early Nonresponders to Atypical Antipsychotic Therapy

J. Kane, H. Ascher-Svanum, B. Kinon, 2022 .

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

J. Haro, H. Ascher-Svanum, Michihiro Takahashi, 2012 .

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

H. Ascher-Svanum, D. Faries, Baojin Zhu, 2009, BMC Research Notes.

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

C. Correll, H. Ascher-Svanum, D. Faries, 2005, BMC psychiatry.

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

H. Ascher-Svanum, B. Kinon, P. Feldman, 2012, Neuropsychiatric disease and treatment.

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

H. Ascher-Svanum, A. Lawson, N. Furiak, 2009, Cost effectiveness and resource allocation : C/E.

Cost Effectiveness and Resource Allocation Cost-effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States

R. Conley, R. Klein, H. Ascher-Svanum, 2022 .

Antipsychotic Monotherapy and Polypharmacy in the Treatment of Outpatients With Schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study

J. Haro, H. Ascher-Svanum, R. Brugnoli, 2012, The Journal of nervous and mental disease.

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

H. Ascher-Svanum, D. Faries, A. Nyhuis, 2009, Cost effectiveness and resource allocation : C/E.

Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.

R. Conley, H. Ascher-Svanum, A. Lawson, 2009, The Journal of clinical psychiatry.

Item response analysis of the Positive and Negative Syndrome Scale

Philip D. Harvey, H. Ascher-Svanum, L. White, 2007, BMC psychiatry.